ONJ in two dental practice-based research network regions
- PMID: 21317245
- PMCID: PMC3144130
- DOI: 10.1177/0022034510387795
ONJ in two dental practice-based research network regions
Abstract
The incidence of osteonecrosis of the jaw (ONJ) in the population is low, but specifics are unknown. Potential risk factors include bisphosphonate treatment, steroid treatment, osteoporosis, and head/neck radiation. This Dental Practice-Based Research Network study estimated ONJ incidence and odds ratios from bisphosphonate exposure and other risk factors using a key word search and manual chart reviews of electronic records for adults aged ≥ 35 yrs enrolled during 1995-2006 in two large health-care organizations. We found 16 ONJ cases among 572,606 cohort members; seven additional cases were identified through dental plan resources. Among 23 cases (0.63 per 100,000 patient years), 20 (87%) had at least one risk factor, and six (26%) had received oral bisphosphonates. Patients with oral bisphosphonates were 15.5 (CI, 6.0-38.7) more likely to have ONJ than non-exposed patients; however, the sparse number of ONJ cases limits firm conclusions and suggests that the absolute risks for ONJ from oral bisphosphonates is low.
Republished in
-
ONJ in two dental practice-based research network regions.Tex Dent J. 2013 Apr;130(4):311-8. Tex Dent J. 2013. PMID: 23767160
Comment in
-
Making a case for defining osteonecrosis of the jaw.J Dent Res. 2011 Apr;90(4):399-401. doi: 10.1177/0022034510396884. Epub 2011 Feb 11. J Dent Res. 2011. PMID: 21317244 Free PMC article. No abstract available.
Similar articles
-
ONJ in two dental practice-based research network regions.Tex Dent J. 2013 Apr;130(4):311-8. Tex Dent J. 2013. PMID: 23767160
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
-
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.J Oral Maxillofac Surg. 2007 Mar;65(3):415-23. doi: 10.1016/j.joms.2006.10.061. J Oral Maxillofac Surg. 2007. PMID: 17307586
-
Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.Am J Health Syst Pharm. 2009 Sep 1;66(17):1541-7. doi: 10.2146/ajhp080251. Am J Health Syst Pharm. 2009. PMID: 19710437 Review.
-
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805682
Cited by
-
A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years.Biomedicines. 2024 Sep 25;12(10):2179. doi: 10.3390/biomedicines12102179. Biomedicines. 2024. PMID: 39457492 Free PMC article.
-
Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases.J Bone Oncol. 2024 Sep 21;48:100634. doi: 10.1016/j.jbo.2024.100634. eCollection 2024 Oct. J Bone Oncol. 2024. PMID: 39381634 Free PMC article.
-
Current state of dental informatics in the field of health information systems: a scoping review.BMC Oral Health. 2022 Apr 19;22(1):131. doi: 10.1186/s12903-022-02163-9. BMC Oral Health. 2022. PMID: 35439988 Free PMC article. Review.
-
Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis-From Pathophysiology to Therapeutic Implications.Int J Mol Sci. 2022 Jan 7;23(2):640. doi: 10.3390/ijms23020640. Int J Mol Sci. 2022. PMID: 35054824 Free PMC article. Review.
-
Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.J Bone Metab. 2021 Nov;28(4):279-296. doi: 10.11005/jbm.2021.28.4.279. Epub 2021 Nov 30. J Bone Metab. 2021. PMID: 34905675 Free PMC article.
References
-
- American Association of Oral and Maxillofacial Surgeons (2007). Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 65:369-376 - PubMed
-
- Bilezikian JP. (2006). Osteonecrosis of the jaw–do bisphosphonates pose a risk? N Engl J Med 355:2278-2281 - PubMed
-
- Cartsos VM, Zhu S, Zavras AI. (2008). Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23-30 - PubMed
-
- Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, et al. (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166-1172 - PubMed
-
- Estefania-Fresco R, Ponte-Fernández N, Aguirre-Urizar JM. (2006). Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Pathol Oral Cir Bucal 11:E456-E461 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
